resulted in Australia having low drug prices relative to most other developed nations.
It has been argued that the current Australian system reduces the profitability of the pharmaceutical industry. As many drug companies are based in the USA they could be expected to hope that the free trade agreement would improve their fortunes in Australia. Whether or not the local pharmaceutical industry will benefit to the same degree as the US companies is unclear.
The pharmaceutical part of the agreement (Annex 2-C) does not appear to contain any drastic changes, but it is open to interpretation. The agreed principles are focused on timely access to innovative pharmaceutical products. This means new drugs must be expeditiously evaluated. There is no suggestion at this stage that the Therapeutic Goods Administration (TGA) will automatically approve drugs which have already been approved by the US Food and Drug Administration. However, there is to be increased regulatory co-operation between the USA and Australia, 'with a view to making innovative medical products more quickly available to their nationals'.
It remains to be seen whether a decision by the TGA not to approve a new drug or a decision not to list the drug on the PBS could be construed to be a breach of the agreement, resulting in referral to the dispute resolution process. In this situation, could it be argued that Australia has not honoured its commitment 'to recognise the value of innovative pharmaceuticals'?
The pharmaceutical industry has been pushing for greater openness in the processes for listing drugs on the PBS. Its efforts have been rewarded with six points of Annex 2-C devoted to transparency. They include the establishment of an independent review process to examine recommendations for listing drugs. The agreement does not specify whether or not this is an appeals mechanism which can overturn decisions. It is also unclear if the review process will be confidential. If the review process is a move towards greater transparency, it will be interesting to know if the drug companies will agree to open assessment of the data supporting their claims. If drugs are going to have a public subsidy, making the data available for public scrutiny is highly desirable.
Part 5 of Annex 2-C allows drug companies to disseminate information to consumers via the internet. Although this activity is regulated by the laws of each country, Australia now has trade agreements with the two westernised countries (New Zealand and USA) that allow direct-to-consumer advertising. 2 Other parts of the agreement also have an impact on pharmaceuticals. Chapter 17 deals with intellectual property rights and several paragraphs refer specifically to pharmaceutical products. 1 Patents can be extended to account for the time the regulatory authorities take to evaluate a drug.
Companies which want to market drugs that are the same or similar to innovator products will not be able to do so for at least five years from the date the innovator product is marketed, unless the innovator company gives permission. The details of the agreement will probably depend on the Medicines Working Group, which will be established 'to promote discussion and mutual understanding of the issues'.
It is unknown if these discussions will be secret, but the only members of the Medicines Working Group will be officials from federal government agencies.
If the official line is that there will be no changes to the PBS, then why were pharmaceuticals included in the agreement? The USA has a legislative requirement for negotiations 'to achieve the elimination of government measures such as price controls and reference pricing which deny full market access for United States products'. 4 Is the US-Australia agreement an exception to this rule? If it is not, inclusion of pharmaceuticals in the agreement could eventually prove to be a costly mistake with potentially adverse consequences for public health.
Are new drugs as good as they claim to be? The article by Wright also states that there is no evidence for reduced gastrointestinal damage from COX-2 inhibitors. He bases this opinion on a single flawed study (CLASS) that had a statistical power of about 45% (that is, less than a 50% chance of detecting any real differences). 6 He neglects to mention the wealth of other data from adequately powered studies that show a significant difference in safety and tolerability between celecoxib and the non-specific NSAIDs. 7, 8, 9, 10, 11, 12, 13 If the COX-2 inhibitors did not represent a cost-effective treatment then they would not be listed on the Pharmaceutical Benefits Scheme. The Pharmaceutical Benefits Advisory Committee makes this decision based on evidence, not opinion.
Dr Simon McErlane

Medical Director
Pfizer Global Pharmaceuticals Pfizer Australia
